,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['breast', 't-dxd', 'mbc']
the audience could not stop clapping at #asco2022 plenary. t-dxd showed significant &amp; meaningful benefit for patients w/ her2-low mbc (~65% of her2 negative pxs). a new era of understanding breast cancer is here. 
Surgeon, researcher, advocate for  transformative and collaborative cancer research